A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

  • STATUS
    Recruiting
  • End date
    Feb 27, 2024
  • participants needed
    35
  • sponsor
    bluebird bio
Updated on 27 January 2021

Summary

Study ALD-104 is an international, non-randomized, open-label, multi-site study in male participants (<or=17 years of age at enrollment) with cerebral adrenoleukodystrophy (CALD). Approximately 35 participants will be infused with Lenti-D Drug Product after myeloablative conditioning with busulfan and fludarabine.

This trial will evaluate the efficacy and safety of autologous cluster of differentiation 34 (CD34+) hematopoietic stem cells, transduced ex-vivo with Lenti-D lentiviral vector, for the treatment of CALD. A subject's blood stem cells will be collected and modified (transduced) using the Lenti-D lentiviral vector encoding human adrenoleukodystrophy protein. After modification (transduction) with the Lenti-D lentiviral vector, the cells will be transplanted back into the subject following myeloablative conditioning.

Details
Condition Cerebral Adrenoleukodystrophy, cald
Treatment Genetic, Genetic, Lenti-D; elivaldogene autotemcel, Lenti-D
Clinical Study IdentifierNCT03852498
Sponsorbluebird bio
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age less than or equal to 17 yrs?
Are you male?
Do you have Cerebral Adrenoleukodystrophy?
Do you have any of these conditions: cald or Cerebral Adrenoleukodystrophy?
Informed consent is obtained from a competent custodial parent or guardian with legal capacity to execute a local Institutional Review Board (IRB)/independent ethics committee (IEC) approved consent. Informed assent will be sought from capable subjects, in accordance with the directive of the IRB/IEC and with local requirements
Males aged 17 years and younger, at the time of parental/guardian consent and, where appropriate, subject assent
Active cerebral ALD as defined by
Elevated very long chain fatty acids (VLCFA) values, and
Active central nervous system (CNS) disease established by central radiographic review of brain MRI demonstrating
Loes score between 0.5 and 9 (inclusive) on the 34-point scale, and ii. Gadolinium enhancement on MRI of demyelinating lesions
NFS less than or equal to (<or=) 1

Exclusion Criteria

Prior receipt of an allogeneic transplant or gene therapy
Use of statins, Lorenzo's Oil, or dietary regimens used to lower VLCFA levels. Note: subjects must discontinue use of these medications at time of consent
Receipt of an investigational study drug or procedure within 3 months before Screening that might confound study outcomes. Use of investigational study drugs is prohibited throughout the course of the study
Any conditions that make it impossible to perform MRI studies (including allergies to anesthetics or contrast agents)
Hematological compromise as evidenced by
Peripheral blood absolute neutrophil count (ANC) count <1500 cells/ cubic millimeter (mm3), and either
Platelet count <100,000 cells/mm3, or
Hemoglobin <10 gram per deciliter (g/dL)
Hepatic compromise as evidenced by
Aspartate transaminase (AST) value >2.5 upper limit of normal (ULN)
Alanine transaminase (ALT) value >2.5 ULN
Total bilirubin value >3.0 milligram per deciliter (mg/dL), except if there is a diagnosis of Gilbert's Syndrome and the subject is otherwise stable
Baseline estimated glomerular filtration rate <70 milliliter per minute (mL/min)/1.73 square meter (m2)
Cardiac compromise as evidenced by left ventricular ejection fraction <40 percent (%)
Immediate family member with a known or suspected Familial Cancer Syndrome
Clinically significant uncontrolled, active bacterial, viral, fungal, parasitic, or prion associated infection
Positive for HIV, hepatitis B or C virus, or human T lymphotrophic virus 1 (HTLV-1)
Any clinically significant cardiovascular, hematological, or pulmonary disease, or other disease or condition that would be contraindicated for any of the other study procedures
Absence of adequate contraception for fertile subjects
Any contraindications to the use of Granulocyte colony-stimulating factor (G-CSF) or plerixafor during the mobilization of hematopoietic stem cells, and any contraindications to the use of busulfan or fludarabine, including known hypersensitivity to the active substances or to any of the excipients in their formulations
Known hypersensitivity to protamine sulfate
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note